ZOGENIX INC's gross profit margin for the fourth quarter of its fiscal year 2014 has significantly decreased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. ZOGENIX INC has average liquidity. Currently, the Quick Ratio is 1.35 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 200.00% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY14||Q4 FY13|
|Net Sales ($mil)||14.9||9.92|
|Net Income ($mil)||-20.52||-35.62|
|Balance Sheet||Q4 FY14||Q4 FY13|
|Cash & Equiv. ($mil)||50.71||72.02|
|Total Assets ($mil)||202.84||112.5|
|Total Debt ($mil)||23.15||28.8|
|Profitability||Q4 FY14||Q4 FY13|
|Gross Profit Margin||-22.63||29.17|
|Return on Assets||4.23||-71.86|
|Return on Equity||15.53||-438.81|
|Debt||Q4 FY14||Q4 FY13|
|Share Data||Q4 FY14||Q4 FY13|
|Shares outstanding (mil)||141.05||138.93|
|Div / share||0.0||0.0|
|Book value / share||0.39||0.13|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||3719869.0||1966780.0|
SELL. ZOGENIX INC's P/E ratio indicates a significant premium compared to an average of 31.65 for the Pharmaceuticals industry and a significant premium compared to the S&P 500 average of 19.41. Conducting a second comparison, its price-to-book ratio of 3.34 indicates a premium versus the S&P 500 average of 2.74 and a significant discount versus the industry average of 8.05. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|ZGNX 65.50||Peers 31.65||ZGNX NA||Peers 49.24|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
ZGNX is trading at a significant premium to its peers.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|ZGNX NM||Peers 17.70||ZGNX NM||Peers 1.13|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ZGNX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
ZGNX's negative PEG ratio makes this valuation measure meaningless.
|ZGNX 3.34||Peers 8.05||ZGNX 102.77||Peers 32.33|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ZGNX is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ZGNX is expected to have an earnings growth rate that significantly exceeds its peers.
|ZGNX 4.56||Peers 7.15||ZGNX 22.77||Peers 12.73|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ZGNX is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
ZGNX has a sales growth rate that significantly exceeds its peers.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV